Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Infliximab is:

An IgG1 chimeric monoclonal antibody against TNF α. **Explanation:** **Infliximab** is a potent biological agent used in the management of autoimmune conditions like Rheumatoid Arthritis, Crohn’s disease, and Psoriasis. 1. **Why Option A is Correct:** Infliximab is a **chimeric** monoclonal antibody. In pharmacology, "chimeric" means it is composed of a combination of mouse (murine) variable regions (~25%) and human constant regions (~75%). It belongs to the **IgG1** subclass and works by binding with high affinity to both soluble and transmembrane forms of **TNF-α**, neutralizing its pro-inflammatory effects. 2. **Why Other Options are Incorrect:** * **Option B:** **Adalimumab** and **Golimumab** are examples of **fully human** monoclonal antibodies against TNF-α. They are preferred in some cases because they have lower immunogenicity compared to chimeric antibodies. * **Option C:** **Etanercept** is the **P75 TNF receptor fusion protein**. It acts as a "decoy receptor" that binds to TNF molecules in the circulation, preventing them from interacting with cell surface receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Nomenclature Hack:** The suffix **"-ximab"** denotes a **chi**meric antibody (e.g., Infliximab, Rituximab), while **"-umab"** denotes a fully h**uma**n antibody (e.g., Adalimumab). * **Pre-treatment Screening:** Before starting any TNF-α inhibitor, patients **must** be screened for **Latent Tuberculosis** (via TST or IGRA) and Hepatitis B, as these drugs can cause reactivation of these infections. * **Adverse Effects:** Increased risk of serious infections, lymphoma, and worsening of congestive heart failure (CHF).

Q: Which antimetabolite drug is used for the treatment of gout?

Allopurinol. **Explanation:** **Correct Answer: A. Allopurinol** Allopurinol is a structural analogue of **hypoxanthine** [1], [2]. It acts as a potent competitive inhibitor of **Xanthine Oxidase**, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid [1], [2]. By inhibiting this pathway, allopurinol reduces plasma uric acid levels [2], making it the drug of choice for the chronic management of both primary and secondary gout [1], [2]. It is classified as an antimetabolite because it mimics a natural purine base to interfere with enzymatic processes [1], [2]. **Analysis of Incorrect Options:** * **B. Zidovudine (AZT):** This is a pyrimidine analogue (nucleoside reverse transcriptase inhibitor - NRTI) used in the treatment of **HIV/AIDS**. It inhibits viral DNA synthesis and has no role in uric acid metabolism. * **C. Azathioprine:** While this is an immunosuppressant antimetabolite (prodrug of 6-mercaptopurine), it is used for organ transplants and autoimmune diseases. Notably, it has a significant **drug interaction** with Allopurinol; since Allopurinol inhibits xanthine oxidase (the enzyme that degrades 6-MP), it can lead to life-threatening azathioprine toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Acute Gout Warning:** Never start Allopurinol during an acute attack of gout, as a sudden change in serum urate levels can precipitate or worsen the flare. * **HLA-B*5801:** Screening for this allele is recommended in certain populations (e.g., Han Chinese, Thai) before starting Allopurinol to prevent **Stevens-Johnson Syndrome (SJS)** or Toxic Epidermal Necrolysis (TEN). * **Febuxostat:** A newer, non-purine selective inhibitor of xanthine oxidase used in patients intolerant to Allopurinol.

Q: All of the following statements about mycophenolate mofetil are true except?

It is highly nephrotoxic. ### Explanation **Mycophenolate Mofetil (MMF)** is a potent immunosuppressant widely used in organ transplantation and autoimmune disorders. **Why Option D is the Correct Answer (The "Except"):** Unlike Calcineurin inhibitors (CNIs) like **Cyclosporine** and **Tacrolimus**, Mycophenolate Mofetil is **not nephrotoxic**. In fact, it is often used as a "renal-sparing" agent to reduce the dose of CNIs in transplant patients to preserve kidney function. Its primary toxicities are hematological (bone marrow suppression) and gastrointestinal. **Analysis of Other Options:** * **Option A (Prodrug):** This is true. MMF is a prodrug that is rapidly hydrolyzed in the liver to its active metabolite, **Mycophenolic Acid (MPA)**. * **Option B (GI Toxicity):** This is true. Gastrointestinal side effects (nausea, vomiting, abdominal pain, and diarrhea) are the **most common** adverse effects, often requiring dose adjustments. * **Option C (Use in Transplant):** This is true. MMF is a cornerstone in preventing acute rejection in solid organ transplants (kidney, heart, liver), often used in combination with steroids and CNIs. **Mechanism of Action (High-Yield):** MMF acts by **non-competitive, reversible inhibition of Inosine Monophosphate Dehydrogenase (IMPDH)**. This enzyme is crucial for the *de novo* synthesis of guanosine nucleotides. Since T and B lymphocytes rely solely on the *de novo* pathway (lacking the salvage pathway), MMF selectively inhibits lymphocyte proliferation. **Clinical Pearls for NEET-PG:** 1. **Drug of choice:** MMF is the preferred drug for **Lupus Nephritis**. 2. **Teratogenicity:** It is highly teratogenic (Category D), associated with "Mycophenolate embryopathy" (ear and facial defects). 3. **Monitoring:** Unlike Tacrolimus, routine Therapeutic Drug Monitoring (TDM) is generally not mandatory for MMF.

Q: Which is the most potent analgesic agent?

Sufentanil. **Explanation:** The potency of an opioid analgesic is determined by its affinity for the **mu (μ) opioid receptors**. Among the synthetic phenylpiperidine derivatives (fentanyl congeners), **Sufentanil** is the most potent agent currently used in clinical practice. **Why Sufentanil is correct:** Sufentanil is approximately **5 to 10 times more potent than Fentanyl** and nearly **500 to 1,000 times more potent than Morphine**. Its high lipid solubility and high receptor affinity allow for rapid onset and intense analgesia, making it ideal for cardiac surgeries and as an adjunct in balanced anesthesia. **Analysis of Incorrect Options:** * **Fentanyl:** While highly potent (approx. 100 times more than morphine), it serves as the prototype for this class but is significantly less potent than its derivative, Sufentanil. * **Remifentanil:** Its potency is roughly equal to Fentanyl. Its unique feature is its metabolism by **plasma and tissue esterases**, leading to an ultra-short duration of action (half-life Fentanyl ≈ Remifentanil > Alfentanil > Morphine. 2. **Context-Sensitive Half-Life:** Remifentanil has the shortest context-sensitive half-life, making it the drug of choice for continuous infusions where rapid recovery is required. 3. **Alfentanil** has the fastest onset of action despite being less potent. 4. **Sufentanil** is associated with the highest risk of chest wall rigidity (Stiff Man Syndrome) if injected rapidly.

Q: What is the analgesic of choice in a patient with hemophilia and rheumatoid arthritis?

Acetaminophen. **Explanation:** The core clinical challenge in this scenario is managing pain in a patient with a pre-existing bleeding disorder (**Hemophilia**). **Why Acetaminophen is the Correct Choice:** Acetaminophen (Paracetamol) is the preferred analgesic because it is a **selective CNS prostaglandin synthesis inhibitor** with negligible effects on peripheral COX-1 and COX-2 enzymes. Unlike NSAIDs, it does not inhibit platelet aggregation or prolong bleeding time. In a hemophilic patient, maintaining intact platelet function is critical to prevent spontaneous or exacerbated bleeding episodes. **Analysis of Incorrect Options:** * **Aspirin:** It is strictly contraindicated. Aspirin causes **irreversible inhibition of COX-1**, leading to prolonged anti-platelet effects (7–10 days). In hemophilia, this significantly increases the risk of life-threatening hemorrhage. * **Ibuprofen:** As a non-selective NSAID, it causes reversible inhibition of platelet aggregation and can irritate the gastric mucosa, potentially leading to GI bleeds—a high risk for hemophiliacs. * **Phenylbutazone:** This is a potent NSAID with a high side-effect profile, including bone marrow suppression (agranulocytosis) and significant GI irritation. It is rarely used today and is unsafe in patients with bleeding tendencies. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Acetaminophen is the DOC for pain/fever in patients with peptic ulcers, bleeding disorders, and children with viral infections (to avoid **Reye’s Syndrome**). * **RA Management:** While NSAIDs are typically first-line for RA inflammation, in the presence of hemophilia, systemic NSAIDs are avoided. If inflammation is severe, selective COX-2 inhibitors (like Celecoxib) may be used with caution, but Acetaminophen remains the safest initial analgesic. * **Toxicity:** The toxic metabolite of Acetaminophen is **NAPQI**, which is neutralized by **N-acetylcysteine (NAC)**.

Q: Which of the following patient characteristics is a possible reason for the use of celecoxib in the treatment of arthritis?

History of peptic ulcer disease. **Explanation:** **Why Option C is Correct:** Celecoxib is a **selective COX-2 inhibitor**. Traditional NSAIDs (like Ibuprofen or Naproxen) inhibit both COX-1 and COX-2 enzymes. COX-1 is constitutively expressed in the gastric mucosa, where it produces cytoprotective prostaglandins ($PGE_2$ and $PGI_2$) that maintain the mucosal barrier. By sparing COX-1 and selectively inhibiting COX-2 (the enzyme induced during inflammation), celecoxib significantly reduces the risk of **gastric ulcers and GI bleeding** [1], [2]. Therefore, it is the preferred NSAID for patients with a history of peptic ulcer disease (PUD) or those at high risk for GI complications [1]. **Why Other Options are Incorrect:** * **Option A:** Celecoxib contains a **sulfonamide moiety**. It is contraindicated in patients with a known history of severe allergic reactions (like Stevens-Johnson Syndrome) to sulfonamides. * **Option B:** While NSAIDs are used to treat acute gout, celecoxib offers no specific advantage over non-selective NSAIDs for gout. In fact, traditional NSAIDs like Indomethacin are often preferred. * **Option D:** There is no specific therapeutic indication or advantage for using celecoxib in patients with Type 2 Diabetes Mellitus. **NEET-PG High-Yield Pearls:** 1. **Cardiovascular Risk:** While GI-friendly, selective COX-2 inhibitors (except perhaps Celecoxib at low doses) are associated with an increased risk of **thrombotic cardiovascular events** (MI/Stroke) because they inhibit $PGI_2$ (vasodilator/anti-aggregatory) without affecting Thromboxane $A_2$ (vasoconstrictor/pro-aggregatory) [2], [3]. 2. **Renal Effects:** Selective COX-2 inhibitors carry the **same risk of nephrotoxicity** as non-selective NSAIDs, as both enzymes play a role in renal perfusion. 3. **Sulfonamide Allergy:** Celecoxib is the only NSAID with a sulfonamide group; always screen for "sulfa" allergies before prescribing.

Q: An analgesic 'X' acts through opioid as well as additional spinal monoaminergic mechanisms. Which of the following can be 'X'?

Tramadol. ### Explanation **Correct Option: A (Tramadol)** Tramadol is a unique, centrally acting analgesic characterized by a **dual mechanism of action**: 1. **Opioid Mechanism:** It is a weak $\mu$-opioid receptor agonist. 2. **Non-Opioid (Monoaminergic) Mechanism:** It inhibits the neuronal reuptake of **Norepinephrine (NE)** and **Serotonin (5-HT)** in the spinal cord. This enhances the descending inhibitory pathways of pain transmission. This dual action allows for effective analgesia with a lower risk of respiratory depression and constipation compared to traditional opioids. **Analysis of Incorrect Options:** * **B. Etioheptazine:** This is an older, non-opioid analgesic structurally related to pethidine but lacks significant opioid receptor activity or monoaminergic reuptake inhibition. * **C. Dextropropoxyphene:** A weak $\mu$-opioid agonist. While it was used for mild-to-moderate pain, it does not possess the specific spinal monoaminergic reuptake inhibition seen in Tramadol. (Note: It has been banned in many regions due to cardiotoxicity). * **D. Alfentanil:** A potent, short-acting phenylpiperidine derivative that acts as a pure $\mu$-opioid agonist. It is primarily used in anesthesia and does not have a monoaminergic component. **High-Yield Clinical Pearls for NEET-PG:** * **Tapentadol:** Similar to Tramadol, it is a $\mu$-agonist and NE reuptake inhibitor (NRI), but it has negligible effect on Serotonin. * **Side Effects:** Tramadol can lower the **seizure threshold** (caution in epileptics) and may cause **Serotonin Syndrome** if combined with SSRIs or MAO inhibitors. * **Metabolism:** It is a prodrug converted to its active metabolite (O-desmethyltramadol) by **CYP2D6**.

Q: Which of the following drugs is associated with the highest cardiac mortality?

Rofecoxib. **Explanation:** **Rofecoxib (Option A)** is the correct answer because it was voluntarily withdrawn from the global market (2004) due to a significantly increased risk of **cardiovascular events**, specifically myocardial infarction and stroke. The underlying medical concept involves the **imbalance of Prostaglandins**. Rofecoxib is a highly selective **COX-2 inhibitor**. While COX-2 inhibition reduces inflammatory Prostaglandin I2 (Prostacyclin) in the vascular endothelium—which is a potent vasodilator and inhibitor of platelet aggregation—it does **not** inhibit COX-1 in platelets. This leaves the production of **Thromboxane A2 (TXA2)**—a potent vasoconstrictor and platelet aggregator—unopposed. This pro-thrombotic state leads to increased cardiac mortality. **Analysis of Incorrect Options:** * **Nicorandil (Option B):** A potassium channel opener used in angina; it is generally cardioprotective and does not increase mortality. * **Losartan (Option C):** An Angiotensin Receptor Blocker (ARB) that **decreases** cardiac mortality and morbidity, especially in patients with hypertension, heart failure, and diabetic nephropathy. * **Metoprolol (Option D):** A cardioselective beta-blocker proven to **reduce** mortality in patients post-myocardial infarction and in chronic heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **VIGOR Trial:** The landmark study that identified the increased CV risk of Rofecoxib compared to Naproxen. * **COX-2 Selectivity:** Celecoxib and Etoricoxib are other members of this class; they are used with extreme caution in patients with pre-existing ischemic heart disease. * **Aspirin Paradox:** Unlike non-selective NSAIDs (like Ibuprofen), COX-2 inhibitors do not interfere with the antiplatelet effect of low-dose Aspirin, but their intrinsic pro-thrombotic risk remains a concern.

Q: What is the mechanism of action of cyclosporine?

Decreases transcription of the IL-2 gene. **Mechanism of Action: Cyclosporine** **Correct Answer: C. Decreases transcription of the IL-2 gene** **Explanation:** Cyclosporine is a potent immunosuppressant belonging to the **calcineurin inhibitor** class. Its mechanism involves several steps: 1. Cyclosporine enters the T-cell and binds to a specific cytoplasmic receptor protein called **Cyclophilin**. 2. The Cyclosporine-Cyclophilin complex binds to and inhibits **Calcineurin**, a phosphatase enzyme. 3. Under normal conditions, calcineurin dephosphorylates **NFAT** (Nuclear Factor of Activated T-cells), allowing it to enter the nucleus. 4. By inhibiting calcineurin, cyclosporine prevents the dephosphorylation and nuclear translocation of NFAT. 5. Consequently, there is a failure to activate the promoter region of the **Interleukin-2 (IL-2) gene**, leading to **decreased transcription** and production of IL-2. Since IL-2 is the primary driver for T-cell proliferation, the immune response is suppressed. **Why other options are incorrect:** * **Option A:** Drugs like **Basiliximab** and **Daclizumab** are monoclonal antibodies that specifically block the IL-2 receptor (CD25). * **Option B:** TNF-alpha inhibitors include drugs like **Etanercept, Infliximab, and Adalimumab**, used primarily in Rheumatoid Arthritis and IBD. * **Option D:** Cyclosporine targets **activated** T-cells (specifically the G0 or G1 phase). It does not target inactivated cells. **High-Yield NEET-PG Pearls:** * **Side Effects:** Nephrotoxicity (most common/serious), Gingival Hyperplasia, Hirsutism, and Hypertension. * **Metabolism:** Metabolized by **CYP3A4**; avoid grapefruit juice as it increases drug levels. * **Clinical Use:** Organ transplantation (prophylaxis of graft rejection) and autoimmune disorders like Psoriasis and Uveitis. * **Comparison:** **Tacrolimus** has a similar mechanism but binds to **FK-Binding Protein (FKBP-12)** instead of cyclophilin.

Question 1

Infliximab is:

Accepted Answer

An IgG1 chimeric monoclonal antibody against TNF α

Answer

An IgG1 fully human monoclonal antibody against TNF α

Answer

A P75 TNF receptor fusion protein

Answer

None of the above

Question 2

Which antimetabolite drug is used for the treatment of gout?

Accepted Answer

Allopurinol

Answer

Zidovudine

Answer

Azathioprine

Answer

None of the above

Question 3

All of the following statements about mycophenolate mofetil are true except?

Accepted Answer

It is highly nephrotoxic

Answer

It is a prodrug

Answer

Gastrointestinal toxicity is common

Answer

It is used in transplant recipients where other drugs are not effective

Question 4

Which is the most potent analgesic agent?

Accepted Answer

Sufentanil

Answer

Fentanyl

Answer

Remifentanil

Answer

Allentanil

Question 5

What is the analgesic of choice in a patient with hemophilia and rheumatoid arthritis?

Accepted Answer

Acetaminophen

Answer

Ibuprofen

Answer

Aspirin

Answer

Phenylbutazone

Question 6

Which of the following patient characteristics is a possible reason for the use of celecoxib in the treatment of arthritis?

Accepted Answer

History of peptic ulcer disease

Answer

History of severe rash after treatment with a sulfonamide antibiotic

Answer

History of gout

Answer

History of type 2 DM

Question 7

An analgesic 'X' acts through opioid as well as additional spinal monoaminergic mechanisms. Which of the following can be 'X'?

Accepted Answer

Tramadol

Answer

Etioheptazine

Answer

Dextropropoxyphene

Answer

Alfentanil

Question 8

Which of the following drugs is associated with the highest cardiac mortality?

Accepted Answer

Rofecoxib

Answer

Nicorandil

Answer

Losartan

Answer

Metoprolol

Question 9

What is the mechanism of action of cyclosporine?

Accepted Answer

Decreases transcription of the IL-2 gene

Answer

Inhibits IL-2 receptors

Answer

Inhibits TNF alpha

Answer

Targets inactivated T cells

Question 10

Which of the following statements about aspirin is TRUE?

Accepted Answer

Aspirin suppresses flushing associated with a large dose of nicotinic acid.

Answer

In an afebrile patient, acute overdose of aspirin produces hypothermia.

Answer

Aspirin therapy prevents granulomatous lesions and cardiac complications of acute rheumatic fever.

Answer

Long-term aspirin therapy increases the risk of developing colon cancer.

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?